Keyword: Novartis


Sandoz Spin-off from Novartis to Start on October 4, 2023

25.09.2023 -

Novartis today confirmed the plan to spin off 100% of its generic drugs arm Sandoz, with trading of the new company’s shares as well as ADRs (American Depositary Receipts...


Novartis Completes Acquisition of Chinook Therapeutics

14.08.2023 -

Novartis has completed its acquisition of US biopharma Chinook Therapeutics. The acquisition, which was announced in June, has a value of up to $3.5 billion.


Novartis Divests Ophthalmology Assets to Bausch + Lomb for Up to $2.5 Billion

03.07.2023 -

Novartis has signed an agreement to divest its 'front of eye' ophthalmology assets to Bausch + Lomb, a global eye health company. The transaction is valued at up to $2.5...


Novartis Takes Chinook Therapeutics for $3.5 billion

15.06.2023 -

Novartis has agreed to acquire US biopharma Chinook Therapeutics for $3.5 billion. Chinook has two late-stage drugs in development – Atrasentan and Zigakibart – to treat...


Sandoz in Biosimilars Pact with Just – Evotec Biologics

12.05.2023 -

As Novartis moves toward shedding generics subsidiary Sandoz, which it touts as a global leader in off-patent generic and biosimilar drugs, Sandoz has agreed a multi-year...


Sangamo Reviews Options as Drugmakers Terminate Deals

22.03.2023 -

US biotech Sangamo Therapeutics is studying alternative options to advance its neurological disease programs after both Novartis and Biogen ended their respective...


Sandoz Builds Biologics Plant in Slovenia

17.03.2023 -

Sandoz, the generics and biosimilars arm of Swiss drugmaker Novartis, has signed a Memorandum of Understanding to build a biologics production plant in Lendava, Slovenia...


EMA Reviewing Approval of Novartis’ Adakveo

31.01.2023 -

The European Medicines Agency (EMA) said its Committee for Medicinal Products for Human Use (CHMP) has begun reviewing its marketing authorization for Novartis’ Adakveo...